Disturbance of Redox Homeostasis in Down Syndrome: Role of Iron Dysmetabolism
Overview
Biology
General Medicine
Affiliations
Down Syndrome (DS) is the most common genetic form of intellectual disability that leads in the majority of cases to development of early-onset Alzheimer-like dementia (AD). The neuropathology of DS has several common features with AD including alteration of redox homeostasis, mitochondrial deficits, and inflammation among others. Interestingly, some of the genes encoded by chromosome 21 are responsible of increased oxidative stress (OS) conditions that are further exacerbated by decreased antioxidant defense. Previous studies from our groups showed that accumulation of oxidative damage is an early event in DS neurodegeneration and that oxidative modifications of selected proteins affects the integrity of the protein degradative systems, antioxidant response, neuronal integrity and energy metabolism. In particular, the current review elaborates recent findings demonstrating the accumulation of oxidative damage in DS and we focus attention on specific deregulation of iron metabolism, which affects both the central nervous system and the periphery. Iron dysmetabolism is a well-recognized factor that contributes to neurodegeneration; thus we opine that better understanding how and to what extent the concerted loss of iron dyshomeostasis and increased OS occur in DS could provide novel insights for the development of therapeutic strategies for the treatment of Alzheimer-like dementia.
Autophagy is a promising process for linking inflammation and redox homeostasis in Down syndrome.
Ma X, Li W, Ma J, Han Z, Deng S, Wang S Front Pharmacol. 2024; 15:1491563.
PMID: 39415838 PMC: 11479988. DOI: 10.3389/fphar.2024.1491563.
Superoxide dismutase and neurological disorders.
Chidambaram S, Anand N, Varma S, Ramamurthy S, Vichitra C, Sharma A IBRO Neurosci Rep. 2024; 16:373-394.
PMID: 39007083 PMC: 11240301. DOI: 10.1016/j.ibneur.2023.11.007.
Ramacieri G, Locatelli C, Semprini M, Pelleri M, Caracausi M, Piovesan A Front Immunol. 2024; 15:1362501.
PMID: 38694501 PMC: 11061464. DOI: 10.3389/fimmu.2024.1362501.
The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome.
Granholm A, Hamlett E J Clin Med. 2024; 13(5).
PMID: 38592182 PMC: 10932364. DOI: 10.3390/jcm13051338.
Down Syndrome Biobank Consortium: A perspective.
Aldecoa I, Barroeta I, Carroll S, Fortea J, Gilmore A, Ginsberg S Alzheimers Dement. 2024; 20(3):2262-2272.
PMID: 38270275 PMC: 10984425. DOI: 10.1002/alz.13692.